Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines

Acta Pharmacologica Sinica

Volumn 28, Issue 5, 2007, Pages 712-720

  Yin, Jun Qiang ^a   Shen, Jing Nan ^a   Su, Wei Wei ^a   Wang, Jin ^a   Huang, Gang ^a   Jin, Song ^a   Guo, Qian Chen ^a   Zou, Chang Ye ^a   Li, Hao Miao ^a   Li, Fo Bao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Bufalin; Dihydrofolate reductase; Methotrexate; Osteosarcoma

Indexed keywords

BUFALIN; CISPLATIN; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; METHOTREXATE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; OSTEOSARCOMA CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BUFANOLIDES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; HUMANS; METHOTREXATE; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 34247629598     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00559.x     Document Type: Article

References (30)

1. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001 19 : 292 315.
2. Bramwell VH. Osteosarcomas and other cancers of bone. Curr Opin Oncology 2000 12 : 330 6.
3. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994 12 : 423 31.
4. Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 1997 79 : 411 5.
5. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991 270 : 8 14.
6. Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells 1996 14 : 5 9.
7. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 1993 13 : 1610 8.
8. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002 1587 : 164 73.
9. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999 5 : 621 7.
10. Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004 15 : 151 60.
11. Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 2003 82 : 483 93.
12. Panesar NS. Bufalin radioimmunoassays: in search of the endogenous digitalis-like substance. J Immunoassay 1994 15 : 371 91.
13. Hong Z, Chan K, Yeung HW. Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, Liu-Shen-Wan, by liquid chromatography. J Pharm Pharmacol 1992 44 : 1023 6.
14. Krenn L, Kopp B. Bufadienolides from animal and plant sources. Phytochemistry 1998 48 : 1 29.
15. Watabe M, Kawazoe N, Masuda Y, Nakajo S, Nakaya K. Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 1997 57 : 3097 100.
16. Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K. Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 1998 16 : 779 87.
17. Kawazoe N, Watabe M, Masuda Y, Nakajo S, Nakaya K. Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 1999 18 : 2413 21.
18. Nasu K, Nishida M, Ueda T, Takai N, Bing S, Narahara H, et al. Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod 2005 11 : 817 23.
19. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003 54 : 112 24.
20. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, et al. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993 13 : 323 9.
21. Rui H. Research and development of cancer chemopreventive agents in China. J Cell Biochem Suppl 1997 27 : 7 11.
22. Numazawa S, Shinoki M, Ito H, Yoshida T, Kuroiwa Y. Involvement of Na+,K+-ATPase inhibition in K562 cell differentiation induced by bufalin. J Cell Physiol 1994 160 : 113 20.
23. Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S, et al. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 1994 85 : 645 51.
24. Jing Y, Watabe M, Hashimoto S, Nakajo S, Nakaya K. Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 1994 14 : 1193 98.
25. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003 39 : 615 47.
26. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995 80 : 293 9.
27. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002 277 : 16 547 52.
28. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001 13 : 332 7.
29. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R. Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993 75 : 817 25.
30. Salomons GS, Brady HJ, Verwijs-Janssen M, van Den Berg JD. Hart AA, van Den Berg H, et al. The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer. 1997 71 : 959 65.